vericel
announces
fda
acceptance
biologics
license
application
nexobrid
treatment
severe
thermal
burns
cambridge
globe
newswire
vericel
corporation
nasdaq
vcel
today
announced
food
drug
administration
fda
accepted
filing
recently
submitted
biologics
license
application
bla
concentrate
proteolytic
enzymes
enriched
bromelain
eschar
removal
debridement
adults
deep
thermal
burns
fda
assigned
prescription
drug
user
fee
act
pdufa
target
date
june
addition
fda
communicated
currently
planning
hold
advisory
committee
meeting
discuss
application
fda
acceptance
nexobrid
bla
review
represents
another
important
milestone
toward
goal
providing
new
standard
care
eschar
removal
patients
severe
burns
said
nick
colangelo
president
ceo
vericel
look
forward
together
mediwound
working
fda
bla
review
process
seek
marketing
approval
nexobrid
united
sharon
malka
ceo
mediwound
added
acceptance
nexobrid
bla
major
milestone
mediwound
gratifying
know
nexobrid
one
step
closer
available
help
burn
victims
united
states
thank
investigators
teams
employees
partners
especially
barda
vericel
commitment
vericel
host
virtual
analyst
investor
day
friday
october
est
focus
nexobrid
addition
general
corporate
update
vericel
executives
facilitate
discussions
burn
surgeon
thought
leaders
current
burn
debridement
practices
nexobrid
upon
approval
could
change
current
treatment
paradigm
debridement
severe
thermal
burns
vericel
corporation
vericel
leader
advanced
therapies
sports
medicine
severe
burn
care
markets
company
markets
two
cell
therapy
products
united
states
autologous
cultured
chondrocytes
porcine
collagen
membrane
autologous
cellularized
scaffold
product
indicated
repair
symptomatic
single
multiple
cartilage
defects
knee
without
bone
involvement
adults
cultured
epidermal
autografts
permanent
skin
replacement
treatment
patients
deep
dermal
burns
greater
equal
total
body
surface
area
company
also
holds
exclusive
license
mediwound
north
american
rights
biological
orphan
product
debridement
severe
thermal
burns
funding
technical
support
mediwound
development
nexobrid
provided
biomedical
advanced
research
development
authority
barda
information
please
visit
company
website
registered
trademarks
vericel
corporation
registered
trademark
mediwound
used
license
vericel
corporation
vericel
corporation
rights
reserved
cautionary
note
regarding
statements
vericel
cautions
statements
statements
historical
fact
included
press
release
address
activities
events
developments
expect
believe
anticipate
may
occur
future
statements
although
believe
reasonable
basis
statements
contained
herein
based
current
expectations
future
events
affecting
us
subject
risks
assumptions
uncertainties
factors
difficult
predict
many
beyond
control
actual
results
may
differ
materially
expressed
implied
statements
press
release
statements
often
always
made
use
words
phrases
anticipates
intends
estimates
plans
expects
continues
believe
guidance
outlook
target
future
potential
goals
similar
words
phrases
future
conditional
verbs
would
could
may
similar
expressions
specifically
press
release
contains
statements
concerning
anticipated
progress
development
objectives
expectations
commercial
potential
nexobrid
among
factors
may
cause
results
materially
different
stated
herein
inherent
uncertainties
associated
timing
conduct
clinical
trial
product
development
activities
ability
successfully
develop
commercialize
nexobrid
including
commercial
growth
potential
market
demand
product
availability
funding
barda
agreement
mediwound
use
connection
nexobrid
development
activities
competitive
developments
whether
fda
provide
marketing
approval
nexobrid
united
states
risks
related
timing
conduct
next
study
impact
applicable
laws
regulations
uncertainties
associated
scope
scale
duration
impact
pandemic
example
unable
predict
pandemic
affect
overall
healthcare
infrastructure
including
pace
governmental
agencies
fda
review
approve
regulatory
submissions
additional
quarantines
requirements
shelter
home
incremental
mitigation
efforts
also
may
impact
ability
source
supplies
operations
ability
sell
support
use
nexobrid
future
significant
factors
discussed
greater
detail
vericel
annual
report
form
year
ended
december
filed
securities
exchange
commission
sec
february
vericel
quarterly
report
form
quarter
ended
june
filed
sec
august
filings
sec
statements
reflect
views
date
hereof
vericel
assume
specifically
disclaims
obligation
update
statements
reflect
change
views
events
circumstances
occur
date
release
except
required
law
